Humacyte, Inc. (NASDAQ:HUMAW – Get Free Report) shares dropped 1.7% during trading on Tuesday . The company traded as low as $1.58 and last traded at $1.76. Approximately 20,514 shares were traded during mid-day trading, a decline of 16% from the average daily volume of 24,454 shares. The stock had previously closed at $1.79.
Humacyte Stock Down 1.7 %
The business has a fifty day moving average of $1.70 and a 200 day moving average of $1.96.
Humacyte Company Profile
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Featured Articles
- Five stocks we like better than Humacyte
- What Are Some of the Best Large-Cap Stocks to Buy?
- Disney: Forging a 3-Headed Sports Streaming Giant With Fubo Deal
- Top Stocks Investing in 5G Technology
- How Buffett’s Best and Worst Stock Bets Have Fared 5 Years Later
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Bill Ackman’s Bold Case for Fannie Mae and Freddie Mac
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
